Inflammation in Mild Cognitive Impairment due to Parkinson’s disease, Lewy Body disease and Alzheimer’s disease by King E et al.
1 
 
Inflammation in Mild Cognitive Impairment due to Parkinson’s disease, Lewy Body 
disease and Alzheimer’s disease 
 
1Eleanor King, 1John O’Brien, 1Paul Donaghy, 2Caroline H. Williams-Gray, 1Rachael A. Lawson, 
1Christopher M. Morris, 1Nicola Barnett, 1Kirsty Olsen, 1Carmen Martin-Ruiz, 1David Burn, 1Alison J. 
Yarnall, 1John-Paul Taylor, 3Gordan Duncan, 4Tien K. Khoo and 1Alan Thomas 
 
1Institute of Neuroscience, Campus for Aging and Vitality, Newcastle upon Tyne, United Kingdom 
2John Van Geest Centre for Brain Repair, Department of Clinical Neurosciences, Cambridge 
University, United Kingdom 
3Department of Medicine for the Elderly, Western General Hospital, Edinburgh, United Kingdom 
4Menzies Institute of Health, Queensland, Australia 
 
 
Corresponding author: Dr Eleanor King 
3rd Floor Biomedical Research Building 
Campus for Ageing and Vitality 
Newcastle University 
Newcastle upon Tyne 
NE4 5PL 
0191 208 1318 
0191 208 1301 
Eleanor.king@newcastle.ac.uk 
 
 
 
 
Manuscript word count: 3004 
Abstract word count: 250 
Tables: 2 
Figures: 1 
References: 30 
 
2 
 
 
Acknowledgements 
 
We thank Claire Kolenda and Craig Parker for the processing of the plasma samples. 
 
We also thank Mr B. Laidler and friends for their donations to our research in Lewy body 
dementia. 
 
 
 
Funding Sources 
 
The LewyPro work was funded by the National Institute for Health Research (NIHR) Newcastle Biomedical 
Research Centre in Lewy Body Dementia based at Newcastle upon Tyne NHS Foundation Trust and 
Newcastle University and The Royal College of Psychiatrists Pathfinder Fellowship. 
 
ICICLE-PD was funded by Parkinson’s UK (J-0802, G-1507). The research was supported by the Lockhart 
Parkinson’s Disease Research Fun, the National Institute for Health Research (NIRH) Newcastle 
Biomedical Research Unit based at Newcastle Upon Tyne Hospitals NHS Foundation Trust and Newcastle 
University and a NUIHR Biomedical Research Centre award to the University of 
Cambridge/Addenbrooke’s Hospital 
 
 
 
Shared Data Declaration 
 
The data that support the findings of tis study are available from the corresponding author upon 
reasonable request. 
 
 
 
 
 
 
3 
 
 
Abstract 
 
Background 
 
Inflammation appears to play a role in the progression of neurodegenerative diseases. However, little 
is known about inflammation during early stages of cognitive decline or whether this differs in 
different disease groups. We sought to investigate this by assessing the inflammatory profile in 
patients with Parkinson’s disease with the early stages of cognitive impairment (PD-MCI), patients 
with prodromal Alzheimer’s disease (MCI-AD), prodromal Lewy Body disease (MCI-LB) and controls. 
 
Methods 
 
We obtained venous blood samples from participants with PD-MCI (n = 44), PD-normal cognition (n 
= 112) MCI-LB (n = 38), MCI-AD (n = 21) and controls (n = 84). We measured 10 cytokines using Meso 
Scale Discovery V-Plex Plus including interferon-gamma, interleukin (IL)-10, IL-12p70, IL-13, IL-1beta, IL-
2, IL-4, IL-6, IL-8 and tumour necrosis factor alpha. High-sensitivity C–reactive protein was measured. 
 
Results 
 
There was a higher level of inflammation in patients with MCI-AD and MCI-LB compared with controls. 
PD non-cognitively impaired had higher inflammatory markers than controls but there was no 
difference between PD-MCI and controls. There was a decrease in inflammatory markers with 
increasing motor severity based on the Unified Parkinson’s Disease Rating Scale. 
 
Conclusions 
 
Inflammation may be involved in the onset of cognitive decline in patients with MCI-AD and MCI-LB 
but appears to be less prominent PD-MCI albeit in a small data set. This suggests that anti-
inflammatory medications may have most benefit at the earliest stages of neurodegenerative diseases. 
For PD cases, this might be in advance of the development of MCI. 
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Key Points 
 
 There is higher inflammation in patients with MCI-LB and MCI-AD than controls 
 
 The level of inflammation in patients with PD-MCI is similar to controls 
 
 There is an association between decreasing inflammation and worsening motor severity 
 
 Anti-inflammatory medications may be useful in patients with MCI-LB and MCI-AD 
 
 Anti-inflammatory medication may be less useful in patients with PD-MCI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
 
 
 
Introduction 
 
There is a well-established association between neuroinflammation and neurodegenerative diseases [1]. 
Microglia in the brain of patients with Alzheimer’s disease (AD) co-localize with beta-amyloid (Aβ) [2], 
and are better predictors of synaptic loss than Aβ [3]. In Parkinson’s disease (PD) microglia are 
particularly overactive in areas of the brain affected by dopaminergic loss early in disease [4], and 
inflammation may trigger this selective neuronal loss [5]. Furthermore, there appears to be an element 
of inflammation in Parkinson’s disease dementia (PDD), with more widespread microglial activation in 
PDD [6]. 
 
Increased levels of peripheral immune activation has also been repeatedly found in patients with AD 
and PD, suggesting that there may be an element of inter-play between the immune activation in the 
periphery and central neuroinflammation [7, 8]. There have been few studies investigating inflammatory 
markers in PDD, but the reported findings have been mixed [9, 10]. 
 
Questions still arise as to the specific role that inflammation plays in the pathogenesis of 
neurodegenerative diseases. In order to gain a better understanding of this, we must understand the 
time point in disease in which inflammation occurs. 
 
Peripheral cytokine levels in AD reach their peak in early disease [11], and this may precede clinical 
symptoms [12]. Genetic studies have found an association between the Human Leukocyte Antigen and 
increased susceptibility of PD, suggesting that immune mediators may be involved in triggering disease 
onset. Whilst anti-inflammatory agents have no benefit when used in patients with established AD [13] 
observational studies report a reduced risk of AD [14] and PD [15] in people using anti-inflammatory 
medications, implying that their beneficial effects may be at the pre-symptomatic stage. 
 
We found increased inflammation in patients with dementia with Lewy bodies (DLB) at the mild 
cognitive impairment (MCI) stage [16], and recently patients with PD have been found to have increased 
inflammation peripherally compared to controls [17]. PD with mild cognitive impairment (PD-MCI) is a 
particularly relevant sub-group for investigating inflammation in neurodegenerative disease; whilst this 
group have established Parkinson’s disease, they are also at higher risk of dementia. Studying their 
inflammatory profile may give us a clearer understanding of whether inflammation plays a role in the 
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development of dementia in people with PD. We therefore compared the systemic inflammatory 
profiles of patients with MCI from three different subgroups; MCI with AD subtype (MCI-AD), MCI with 
DLB subtype (MCI-LB), and MCI with PD subtype (PD-MCI). 
 
 
Hypothesis 
 
As previous studies have shown that inflammation occurs early in both Alzheimer’s disease and 
Parkinson’s disease, we hypothesised that patients with MCI-AD, MCI-LB and PD-MCI would have higher 
levels of inflammation compared with controls, and that the three MCI groups would all have similar 
levels of inflammation.  
 
 
 
Methods 
 
Participants 
 
MCI-AD and MCI-LB patients were recruited from memory clinics and dementia services in the North East of 
England as part of the National Institute for Health Research (NIHR) LewyPro study [16]. All participants were 
over the age of 60. Participants all met the National Institute on Ageing and Alzheimer’s Association (NIA-AA) 
MCI criteria [18]. MCI-LB was diagnosed if two or more of the four consensus criteria for DLB were present, or 
patients had one of these and abnormal dopaminergic imaging [19]. MCI-AD was diagnosed if none of the core 
symptoms for DLB were met, they had a normal dopaminergic scan, and evidence of cognitive decline as is 
characteristically seen in AD with no evidence of another aetiology. The ‘one year rule’ was applied so that 
no subjects had shown evidence of Parkinsonism for more than a year before the onset of cognitive decline. 
An expert consensus panel (AJT, PD, JPT) reviewed all clinical assessment data to confirm subjects met NIA-
AA MCI criteria, and they rated the presence or absence of each of the four core clinical Lewy Body 
symptoms characteristic of DLB. These assessments were based on taking a clinical history and neurological 
examination, as well as the use of various assessment tools as stated below. Clinicians were blinded to the 
results of the other clinicians and to scan results. Participants were excluded if they had a diagnosis of 
dementia, and if they had severe physical, neurological or psychiatric illness, a past history of alcohol excess 
or use of psychotropic drugs. 
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PD-MCI patients were participants in the Incidence of Cognitive Impairment in Cohorts with Longitudinal 
Evaluation in Parkinson’s Disease study (ICICLE-PD), and we selected those who were aged over 60 [20]. 
Participants with newly diagnosed PD, diagnosed by a movement disorder specialist according to the 
Queen’s Square Brain Bank criteria [21], were recruited from the community and outpatient clinics in 
Newcastle upon Tyne/Gateshead and Cambridgeshire, UK. Participants were classified as having PD-MCI 
at baseline according to the Movement Disorder Society (MDS) PD-MCI modified level 2 criteria [22], if 
they were impaired on two tests in one cognitive domain or on one test in 2 different domains, whereby 
an impairment was classified as being 2 standard deviations below normative means [20]. Participants 
were excluded if they had an MMSE < 24 or an existing diagnosis of dementia. We also included the 
participants with Parkinson’s disease (all those over 60 years old) but without cognitive impairment in 
order to investigate any differences in cytokine levels between patients with PD with normal cognition 
and PD-MCI. 
 
Healthy controls were recruited from community settings. They were all over 60 years old, group-
matched by age either to the LewyPro participants or the ICICLE-PD participants. 
 
All participants provided informed written consent to take part in the study. 
 
 
Assessments 
 
Clinical assessments included an assessment of parkinsonism using the Movement Disorder Society-
Unified Parkinson’s Disease Rating Scale part III (MDS UPDRS III). Illness burden was also assessed using 
the Cumulative Illness Rating Scale (CIRS). An array of neuropsychological and clinical scales were 
performed, dependant on the study [20] ) including a Mini Mental State Examination (MMSE). 
 
 
Measurement of inflammatory markers 
 
Venous blood samples were taken from all participants and processed in line with their study 
protocols. Serum was removed for ICICLE-PD participants and plasma was removed for LewyPro 
participants, and samples were stored at -80 degrees until assays were performed. Cytokine assays 
were measured using the Meso Scale Discovery (MSD) V-PLEX Plus Pro-inflammatory Panel 1, which 
measured Tumour Necrosis Factor (TNF)-alpha, Interleukin (IL)-1beta, IL-2, IL-4, IL-6, IL-8, IL-10, IL-
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12p70, IL-13 and Interferon (IFN)-gamma. High sensitivity C – reactive protein (hs-CRP) was measured 
separately, using V-PLEX CRP for ICICLE-PD samples and using Roche Cobas c702 for LewyPro samples. 
Samples were measured in duplicate for ICICLE-PD samples, and in triplicate for LewyPro samples. 
 
Although it is stated in the MSD manufacturer’s information that there is very little difference between 
using serum and plasma to measure these cytokines [23] we corrected for this by having two separate 
control groups; one matched to the ICICLE-PD cohort using serum and the other matched to the 
LewyPro cohort using plasma. 
 
 
Analysis 
 
All statistical analysis was carried out using IBM SPSS statistics 23. Data distributions were assessed for 
normality using Shapiro-Wilk test. For any non-normally distributed data, where possible log transformations 
were attempted using log(x+1) in order to normalise any skewed data. Associations were sought between 
inflammatory markers and patient demographics to assess for confounding variables. Comparisons were 
made between groups using Analysis of Covariance (ANCOVA) to adjust for age and gender. A significant 
difference was p<0.05, and Bonferroni correction was applied to adjust for multiple variables. Comparisons 
were made between groups using Analysis of Covariance (ANCOVA) to adjust for age and gender. A 
significant difference was p<0.05, and Bonferroni correction was applied to adjust for multiple comparisons. 
Associations were also sought between inflammatory markers and clinical markers of PD motor severity 
(MDS-UPDRS III) and cognitive severity (MMSE) using Pearson’s correlation.  
 
 
 
Results 
 
Demographics 
 
In total 187 subjects were included; 38 had a diagnosis of MCI-LB, 21 of MCI-AD, 44 of PD-MCI and 112 of PD 
with normal cognition. There were 20 controls matched to the participants in the MCI-AD and MCI-LB groups, 
and 64 controls matched to the participants in the PD-MCI group. Participants in the MCI-AD and MCI-LB 
group were older than those in the PD-MCI group, but all groups were age-matched to their respective 
control (table 1). There were differences in gender between groups; all groups had more males than females 
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apart from the MCI-AD group which had more females than males. As expected the MMSE score was higher 
in the control groups than the MCI groups, and MDS UPDRS score was highest in both of the groups with 
Lewy body disease. There was no difference in CIRS score between disease groups and their control groups. 
 
45% of the MCI-LB group were using anti-dementia medications, in comparison to 24% of the MCI-AD group 
and none of the PD-MCI group (table 1). Between 0% and 36% of the participants in each group were using 
anti-inflammatory medications, not including aspirin 75mg. Of these 24 people were using Non-Steroidal 
Anti-Inflammatory Drugs (NSAIDs) and the remaining 35 were using other anti-inflammatory medications 
such steroids and 5-aminosalicylic acid. 
 
 
Cytokine and CRP levels 
 
IL-13 and IL-1beta were removed from further analysis as more than 50% of the samples had non-detectable 
cytokine levels. IL-12p70 was also removed as there was high inter-assay variability. We compared the 
LewyPro participants against LewyPro controls, and we compared the ICICLE-PD patients against the ICICLE-
PD controls. 
 
The MCI-AD and MCI-LB groups had significantly higher levels of IL-10, IL-2 and IL-4 than their control group 
(table 2). TNF-alpha was the only cytokine which was significantly lower in MCI-AD and MCI-LB than their 
controls. There was no significant differences in any of the inflammatory markers measured between PD-MCI 
and their control group. 
 
As an exploratory analysis we investigated whether there were any differences between the MCI 
groups. We found higher levels of IL-10, IL-2 and IL-4 in the MCI-AD and MCI-LB groups than the PD-
MCI group. Due to the differences in age, co-morbidity and sampling methods between these groups, 
this finding is exploratory only and is not therefore recorded in table 2. 
 
 
Correlations 
 
We also sought to investigate whether there were any correlations between PD motor severity using 
the UPDRS III score and cytokine level. Control participants were excluded. Serum and plasma samples 
were both included in the correlation analysis. We found negative correlations between MDS-UPDRS III 
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and IL-2 (r=-0.234, p=0.017) and IL-4 (r=-0.301, p=0.002). (Figure 1). There was no correlation between 
MMSE and inflammatory markers in any of the MCI groups. 
 
 
PD-MCI vs PD 
 
There were no significant differences in any of the cytokines between PD-MCI and PD without 
cognitive impairment, except IL-8 which was significantly higher in PD without MCI (p = 0.026). The PD 
group without cognitive impairment had higher levels of IL-6 and TNF-alpha compared to controls. 
 
 
Discussion 
 
In a previous study we found that peripheral inflammatory markers were high in patients with MCI-AD 
and MCI-LB and normal in patients with DLB and AD dementia, implying that inflammation is highest 
early in disease [16]. In the current study we aimed to investigate this further in patients with PD-MCI. 
We found that whilst patients with MCI-AD and MCI-LB had significantly higher levels of inflammation 
compared to controls, the PD-MCI group had similar levels of inflammatory markers to controls, with 
only slight, non-significant increases in some cytokines. However, inflammatory markers were elevated 
in the PD non-cognitively impaired group. This suggests that inflammation may play a role in the onset 
of cognitive decline leading to AD dementia and DLB, but in PD, inflammation may be most prominent 
prior to the onset of MCI. 
 
The aetiology of PD is debated; however, inflammation is associated with PD and may play a role in the onset 
of disease. It has been suggested that the pathological hallmarks of PD may be triggered by infection of the 
GI tract, contributing to the pre-motor symptoms of PD before also invading the CNS and leading to the 
more characteristic motor symptoms [24]. It is postulated that these infections communicate to the brain via 
the vagus nerve [25] which may then trigger microglial activation, contributing towards dopaminergic 
neuronal damage [26]. Studies have suggested that infections such as Helicobacter Pylori may be a particularly 
important source of enteric inflammation in PD [27]. These findings suggest that infection and therefore 
inflammation are involved in the early, pre-CNS stages of disease. We previously reported that there is 
evidence for increased inflammation in patients with PD, consistent with this, and that increased levels of 
inflammation predict faster disease progression and are associated with cognitive impairment over 3 years 
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of follow up [17]. This suggests not only that early inflammation may be involved in the onset of 
neurodegeneration, but also that a higher level of inflammation predicts a faster rate of decline. 
 
There are few studies investigating inflammation in PDD, and those have found mixed results. Several 
studies have found no significant difference in the level of cytokines in patients with PDD 
compared to PD and controls and one study found that whilst some cytokines are raised in patients with PDD, 
some have lower levels compared to PD and controls [29]. Our findings add that there does not appear to be 
an overall increase in inflammation in PD-MCI. However previous analysis of this ICICLE-PD cohort has shown 
that in patients with PD higher levels of pro-inflammatory cytokines are associated with having a lower 
MMSE over 54 months [17] of longitudinal follow-up. This analysis looked at an older subset of ICICLE-PD 
patients (those over 60) to match the criterion in the MCI-AD and MCI-LB groups. This difference may 
therefore be age related, or may relate to the criteria used to define PD-MCI which may exclusively capture 
those with more advanced cognitive impairment. Furthermore, the current study included only cross 
sectional rather than longitudinal data. Further research is needed, especially prospective studies with serial 
assessments of inflammatory markers, to more fully explore the role that inflammation plays over time in PD. 
 
In the current study we also found a weak but significant association between immune markers (IL-2 
and IL-4) with motor severity, providing preliminary evidence that the immune activation may decrease 
as motor severity increases, although longitudinal studies are needed to test this finding. Furthermore, 
as IL-2 is generally considered to be pro-inflammatory and IL-4 anti-inflammatory, there may also be a 
complex disruption to the balance of pro and anti-inflammatory cytokines, particularly in the early 
stages of disease. There is increasing evidence to suggest that inflammation occurs early in 
neurodegenerative disease progression. In AD, studies have shown that inflammation occurs at the pre-
dementia stages [12], and the level of inflammation seems to decrease with disease progression [11]. This 
finding has been replicated in patients with DLB [16]. A longitudinal study found that increased levels of 
IL-6 increases the risk of PD, suggesting that inflammation occurs at the pre-dementia stage [30]. In 
keeping with the data that we report here indicating that inflammatory markers are raised in PD cases 
without cognitive impairment, previous findings from the ICICLE-PD study have shown that 
inflammatory markers are raised in PD compared to controls [17]. One explanation is that inflammation 
may be highest in the earliest stages of PD and predictive of disease progression, but it is possible that 
this may wane once MCI manifests. 
 
Clinically, this study provides useful information into when anti-inflammatory medications may be of benefit. 
It has been shown in previous studies that inflammation occurs early in MCI-AD and MCI-DLB, and 
12 
 
inflammation decreases as disease progresses to dementia[16], suggesting that anti-inflammatory medications 
may be of use in early stages of disease in these patients. However, this study has shown that there does not 
appear an increase in the level of inflammatory markers in patients with PD-MCI to controls, perhaps because 
inflammation occurs in the early stages of PD, prior to the onset of MCI. In these patients therefore, it seems 
unlikely that there would be any benefit of using anti-inflammatory medications at the onset of MCI.  
 
Our analysis has some important limitations. As we included participants from two separate studies 
there were some differences in demographics and methodology. As outlined in the methodology, the 
way in which participants were recruited differed between participants from the LewyPro study and 
those from the ICICLE-PD study (from memory services and movement disorder services respectively), 
leading to the possibility of selection bias between groups. Whilst plasma was used to measure 
cytokines in the MCI-AD and MCI-LB patients, serum was used for the PD-MCI patients. Although the 
MSD manufacturer states that there is little difference between using plasma and serum for the 
cytokines measured [23], we felt that we were unable to confidently carry out analysis between groups. 
An additional limitation was the small sample size of each MCI group, with fewer than 50 participants in 
each group, affecting the power of analysis. Our findings should therefore be regarded as preliminary 
and in need of replication using consistent methodology across all groups and larger numbers of 
participants in each group. The PD-MCI participants were younger than other MCI groups, and there 
were differences in the gender distribution across groups. Whilst we controlled for this in analysis, 
future studies should match for these variables between MCI groups. Finally, as this was a cross 
sectional study correlation findings between disease severity and inflammatory markers were 
preliminary only, and longitudinal studies are needed in order to further investigate the association.  
 
Conclusion 
 
We found that whilst PD patients without MCI appear to have higher levels of inflammation than 
controls, those with PD-MCI seem to have similar levels of inflammation to controls. Those with MCI-AD 
and MCI-LB had increased inflammatory markers compared to control subjects. Taken with our earlier 
report in patients with PD who had higher levels of inflammation than controls, this suggests that 
immune activation might alter during the course of these diseases, perhaps being highest nearer to 
disease onset at clinical presentation, lower once MCI develops. Future studies should focus on 
investigating the temporal profile of inflammatory markers in prospective studies of patients with PD 
with serial blood samples to ascertain whether, as in dementia, there is early inflammation which 
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decreases as disease progresses, and therefore whether and when during the course of disease anti-
inflammatory medications may be beneficial. 
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Tables 
 
 
 
Table 1: Demographics 
 
 
 Control MCI-AD MCI-LB Control PD-MCI PD-normal 
 LewyPro (n = 21) (n = 38) ICICLE-PD (n = 44) cognition 
 (n = 20)   (n = 64)  (n = 112) 
       
Age 75.9 +/- 1.6 78.5 +/- 1.4 75.6 +/- 1.2 69.5 +/- 0.8 71.1 +/- 0.1 69.5 +/- 6.7 
       
Gender (M:F) 16:4b 7:14a,c 25:13b 34:30e 33:11d,f 44:68e 
       
MMSE 29.1 +/- 0.2b,c 26.5 +/- 0.6a 26.4 +/- 0.4a 29.3 +/- 0.1e,f 27.8 +/- 0.3d 28.9 +/- 1.1d 
       
MDS-UPDRS N/A 15.7 +/- 1.4 27.2 +/- 2.6 N/A 30.4 +/- 1.1 26.3 +/- 10.5 
III       
       
CIRS 6.7 +/- 0.1 9.5 +/- 3.9 9.5 +/-4.3 2.1 +/- 0.2 3.0 +/- 0.3 2.5 +/- 1.5 
       
LEDD 0 0 263.1 +/- 160.6 0 212.7 +/- 128.3 174.1 +/- 156.4 
(mg/day)       
       
Anti- N/A 5 (23.8) 17 (44.7) N/A 0 0 
dementia       
med use (n,       
%)       
Anti- 3 (15%) 1 (4.7%) 0 8 (12.5%) 6 (13.6%) 41 (36.6%) 
inflammatory       
med use (n,       
%)       
 
Table 1: Results are presented as the mean +/- standard deviation. MCI-AD = Mild cognitive impairment 
due to Alzheimer’s disease, MCI-LB = Mild cognitive impairment with Lewy bodies, PD-MCI = 
Parkinson’s disease with Mild Cognitive Impairment, PD-Normal cognition = PD with no cognitive 
impairment. M:F = Male:Female. MMSE = Mini Mental State Examination. MDS-UPDRS III = Movement 
Disorders Society Unified Parkinson’s Disease Rating Scale Part III. CIRS = Cumulative Illness Rating 
Scale. LEDD = levodopa equivalent dose per day. a = significant difference from controls (LewyPro), b = 
significant difference from MCI-AD, c = significant difference from MCI-LB, d = significant difference 
from controls (ICICLE), e = significant difference from PD-MCI, whereby the control LewyPro, MCI-AD 
and MCI-LB groups are being compared against each other, and the control ICICLE-PD and PD-MCI 
groups are being compared against each other. A significant difference is when p ≤ 0.05 after 
Bonferroni correction
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Table 2: Inflammatory markers 
 
 Control MCI-AD MCI-LB Control PD-MCI PD-normal 
 LewyPro   ICICLE-PD   cognition 
CRP, mg/l 3.6 +/- 5.7 3.4 +/- 3.3 4.1 +/- 6.4 3.5 +/- 6.9 4.2 +/- 10.0 3.4 +/- 8.4 
         
IFN-gamma, 7.6 +/- 6.1 8.8 +/- 12.1 6.5 +/- 4.3 10.9 +/- 21.5 15.3 +/- 54.4 8.8 +/- 12.0 
pg/ml         
         
IL-10, pg/ml 0.5 +/- 0.6b,c 0.9 +/- 0.4a 1.0 +/-0.5a 0.2 +/- 0.2 0.2 +/- 0.3 0.4 +/- 0.8 
        
IL-2, pg/ml 0.4 +/-0.4b,c 3.6 +/- 0.9a 3.7 +/- 0.9a 0.08 +/- 0.1 0.3 +/- 0.7 0.1 +/- 0.4 
         
IL-4, pg/ml 0.0 +/- 0.1b,c 0.8 +/- 0.2a 0.8 +/- 0.2a 0.0 +/- 0.1 0.0 +/- 0.0 0.0 +/- 0.0 
        
IL-6, pg/ml 1.7 +/- 1.0 1.1 +/- 3.3 2.9 +/- 10.4 0.7 +/- 7.6f 1.0 +/- 0.2 1.0 +/- 1.8d 
        
IL-8, pg/ml 4.8 +/- 1.5 4.3 +/- 2.9 6.8 +/- 17.5 8.6 +/- 3.8 8.1 +/- 7.5f 10.7 +/- 7.2e 
        
TNF-alpha, 4.3 +/- 1.3b,c 3.1 +/- 3.5 a 2.2 +/- 2.0a 1.9 +/- 1.0f 2.6 +/- 1.7 2.8 +/- 1.3d 
pg/ml         
         
 
 
Table 2: Results are presented as mean +/- standard deviation. MCI-AD = Mild Cognitive Impairment due 
to Alzheimer’s disease, MCI-LB = Mild Cognitive Impairment with Lewy Bodies, PD-MCI = Parkinson’s 
disease with Mild Cognitive Impairment. PD-normal cognition = Parkinson’s disease with no cognitive 
impairment. CRP = C – reactive protein, IFN-gamma = interferon gamma, IL = interleukin, TNF-alpha – 
tumour necrosis factor alpha. a = significant difference from controls (LewyPro), b = significantly different 
from MCI-AD, c = significantly different from MCI-LB, d = significantly different from controls (ICICLE-PD), 
e = significantly different from PD-MCI group, whereby the control (LewyPro), MCI-AD and MCI-LB groups 
are compared, and the control (ICICLE-PD) and PD-MCI groups are compared. A difference is significant 
when p ≤ 0.05 after Bonferroni adjustments. 
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